Australia's Cyclopharm rises as product shows COVID management potential

Cyclopharm

24/05/2022 05:02

** Shares of the radiopharmaceutical firm  CYC.AX  rise as much
as 3.9% to A$1.350, on track for their sharpest single-day pct
jump since May 18  
    ** Co says its proprietary technology Technegas has been
shown to be successful in the diagnosis and management of
COVID-19 symptoms in a study in Ontario  urn:newsml:reuters.com:*:nASX5cWkpQ
    ** Says study creates an opportunity to extend engagement
regarding Technegas from its current core nuclear medicine
customers to respiratory medicine referrers globally 
    ** Stock down 20.7% this year, as of last close, vs a 3.9%
fall in the benchmark S&P/ASX 200 index  .AXJO  


 (Reporting by Roushni Nair in Bengaluru)
 ((Roushni.Nair@thomsonreuters.com;))